首頁 > 市場調查報告書 > 製藥 > 癌症 > 惡性血液疾病相關全球藥物產品線動向及分析

聯絡我們?

市場調查報告書

惡性血液疾病相關全球藥物產品線動向及分析

Global Pipeline Review & Analysis of Hematological Malignancies

出版商	BioSeeker Group AB
出版日期	2007年03月	商品編碼	50858
內容資訊	英文 195 pages
價格	US $ 3553 PDF by E-mail (Single User License)

簡介
目錄
相關商品

惡性血液疾病相關全球藥物產品線動向及分析 是由出版商BioSeeker Group AB在2007年03月所出版的。這份英文市場調查報告書包含195 pages 價格從美金3553起跳。

簡介

惡性血液疾病的治療領域眾多且複雜，也因此新藥的開發更值得期待。新興的治療策略中以免疫療法為主要策略。另外小分子誘導細胞自毁物質及激酶抑制劑也是值得期待的領域。

因醫藥及生物技術領域調查分析，在近年來取得亮眼成績的瑞典市調公司BioSeeker Group針對惡性血液疾病相關動向進行調查分析，並出版經系統整理的調查報告書 "Global Pipeline Review & Analysis of Hematological Malignancies" 。

本報告書內容包括：惡性血液疾病治療藥開發的各個階段及化合物的種類、標的療法策略、訊息傳遞路徑概要等。內容綱要摘記如下：

第1章實施概要

第2章癌症概要

第3章惡性血液疾病領域中的主要企業

第4章血液癌症治療藥物產品線

白血病治療藥產品線
淋巴瘤治療藥產品線

第5章血液癌症的蛋白質標的

白血病中的標的
淋巴瘤中的標的

第6章化合物

化合物概要
利用於血液癌症的生物化合物
利用於血液癌症的化學化合物
利用於血液癌症的天然化合物
依據化合物種類的白血病概要
依據化合物種類的淋巴瘤概要

第7章血液癌症的標的療法

白血病的標的療法
淋巴瘤的標的療法

第8章血液癌症的標的療法策略及化合物的種類

白血病的標的療法策略及化合物的種類
淋巴瘤的標的療法策略及化合物的種類

第9章血液癌症的訊息傳遞路徑

Alpha6Beta4細胞黏著分子訊息傳遞路徑
男性荷爾蒙受體訊息傳遞路徑
B細胞受體訊息傳遞路徑
EGFR1訊息傳遞路徑
ID訊息傳遞路徑
IL-1訊息傳遞路徑
IL-2訊息傳遞路徑
IL-3訊息傳遞路徑
IL-4訊息傳遞路徑
IL-5訊息傳遞路徑
IL-6訊息傳遞路徑
IL-7訊息傳遞路徑
KIT受體訊息傳遞路徑
Notch訊息傳遞路徑
T細胞受體訊息傳遞路徑
TGF-Beta受體訊息傳遞路徑
TNF-Alpha訊息傳遞路徑
WNT訊息傳遞路徑

第10章藥物概要

第11章免責事項

圖表

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

About this report

In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by:

Investigator - Includes 212 investigators and partners
Drug - Includes 237 “active” drugs
Sub-indication - Includes 11 sub-indications
Developmental stage - Includes 8 developmental stages
Compound type - Includes 21 different compounds types
Targeted therapy strategy - Includes 5 different targeted therapy strategies
Target - Includes 97 different protein targets
Signaling pathway - Includes 18 different signaling pathways

All of above “factors” are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each “factor” included in this cutting edge analysis.

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

2.1 LIST OF FIGURES
2.2 LIST OF TABLES

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE

4.1 DRUG PIPELINE BY LEUKEMIA
4.2 DRUG PIPELINE BY LYMPHOMA

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS

5.1 PURSUED TARGETS IN LEUKEMIA
5.2 PURSUED TARGETS IN LYMPHOMA

6 COMPOUNDS

6.1 OVERVIEW OF COMPOUNDS
6.2 PRESENTATION OF BIOLOGICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.3 PRESENTATION OF CHEMICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.4 PRESENTATION OF NATURAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.5 LEUKEMIA BY COMPOUND TYPES
6.6 LYMPHOMA BY COMPOUND TYPE

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS

7.1 TARGETED THERAPIES IN LEUKEMIA
7.2 TARGETED THERPIES IN LYMPHOMA

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN HEMATOLOGICAL CANCERS

8.1 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LEUKEMIA
8.2 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LYMPHOMA

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS

9.1 ALPHA6 BETA4 INTEGRIN SIGNALING PATHWAY
- 9.1.1 DESCRIPTION OF PATHWAY
- 9.1.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.2 ANDROGEN RECEPTOR SIGNALING PATHWAY
- 9.2.1 DESCRIPTION OF PATHWAY
- 9.2.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.3 B CELL RECEPTOR SIGNALING PATHWAY
- 9.3.1 DESCRIPTION OF PATHWAY
- 9.3.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.4 EGFR1 SIGNALING PATHWAY
- 9.4.1 DESCRIPTION OF PATHWAY
- 9.4.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.5 ID SIGNALING PATHWAY
- 9.5.1 DESCRIPTION OF PATHWAY
- 9.5.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.6 IL-1 SIGNALING PATHWAY
- 9.6.1 DESCRIPTION OF PATHWAY
- 9.6.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.7 IL-2 SIGNALING PATHWAY
- 9.7.1 DESCRIPTION OF PATHWAY
- 9.7.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.8 IL-3 SIGNALING PATHWAY
- 9.8.1 DESCRIPTION OF PATHWAY
- 9.8.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.9 IL-4 SIGNALING PATHWAY
- 9.9.1 DESCRIPTION OF PATHWAY
- 9.9.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.10 IL-5 SIGNALING PATHWAY
- 9.10.1 DESCRIPTION OF PATHWAY
- 9.10.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.11 IL-6 SIGNALING PATHWAY
- 9.11.1 DESCRIPTION OF PATHWAY
- 9.11.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.12 IL-7 SIGNALING PATHWAY
- 9.12.1 DESCRIPTION OF PATHWAY
- 9.12.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.13 KIT RECEPTOR SIGNALING PATHWAY
- 9.13.1 DESCRIPTION OF PATHWAY
- 9.13.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.14 NOTCH SIGNALING PATHWAY
- 9.14.1 DESCRIPTION OF PATHWAY
- 9.14.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.15 T CELL RECEPTOR SIGNALING PATHWAY
- 9.15.1 DESCRIPTION OF PATHWAY
- 9.15.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.16 TGF-BETA RECEPTOR SIGNALING PATHWAY
- 9.16.1 DESCRIPTION OF PATHWAY
- 9.16.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.17 TNF-ALPHA SIGNALING PATHWAY
- 9.17.1 DESCRIPTION OF PATHWAY
- 9.17.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.18 WNT SIGNALING PATHWAY
- 9.18.1 DESCRIPTION OF PATHWAY
- 9.18.2 HEMATOLOGICAL CANCER DRUG CANDIDATES

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER

11.1 LIABILITY
11.2 COMPLETENESS

List of Figures

Figure 1: The Hematological Cancer Developmental Pipeline
Figure 2: The Leukemia Developmental Pipeline
Figure 3: The Lymphoma Developmental Pipeline
Figure 4: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 5: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 6: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Molecular Class of Target
Figure 7: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 8: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 9: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Molecular Class of Target
Figure 10: Distribution of Compound Types in the Hematological Malignancies Pipeline
Figure 11: Leukemia Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
Figure 12: Lymphoma Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
Figure 13: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 14: Lymphoma Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 15: Angiogenesis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 16: Apoptosis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 17: Protein Kinase Inhibitors - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 18: Vaccines - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 19: Angiogenesis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 20: Apoptosis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 21: Protein Kinase Inhibitor - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 22: Vaccines - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 23: Drug Candidates Involving the Alpha6 Beta4 Integrin Signaling Pathway for the Treatment of Hematological Cancers
Figure 24: Drug Candidates Involving the Androgen Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 25: Drug Candidates Involving the B Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 26: Drug Candidates Involving the EGFR1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 27: Drug Candidates Involving the ID Signaling Pathway for the Treatment of Hematological Cancers
Figure 28: Drug Candidates Involving the IL-1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 29: Drug Candidates Involving the IL-2 Signaling Pathway for the Treatment of Hematological Cancers
Figure 30: Drug Candidates Involving the IL-3 Signaling Pathway for the Treatment of Hematological Cancers
Figure 31: Drug Candidates Involving the IL-4 Signaling Pathway for the Treatment of Hematological Cancers
Figure 32: Drug Candidates Involving the IL-5 Signaling Pathway for the Treatment of Hematological Cancers
Figure 33: Drug Candidates Involving the IL-6 Signaling Pathway for the Treatment of Hematological Cancers
Figure 34 Drug Candidates Involving the IL-7 Signaling Pathway for the Treatment of Hematological Cancers
Figure 35: Drug Candidates Involving the Kit Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 36: Drug Candidates Involving the Notch Signaling Pathway for the Treatment of Hematological Cancers
Figure 37: Drug Candidates Involving the T Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 38: Drug Candidates Involving the TGF-beta Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 39: Drug Candidates Involving the TNF-alpha Signaling Pathway for the Treatment of Hematological Cancers
Figure 40: Drug Candidates Involving the Wnt Signaling Pathway for the Treatment of Hematological Cancers

List of Tables

Table 1: List of Active Players in the Field of Hematological Malignancies
Table 2: The Leukemia Developmental Pipeline
Table 3: The Lymphoma Developmental Pipeline
Table 4: List of Pursued Protein Targets in Hematological Cancers
Table 5: Hematological Cancer Targets by Investigator and Drug
Table 6: Pursued Targets by Sub-indications of Leukemia
Table 7: Pursued Targets by Sub-indications of Lymphoma
Table 8: Drug Candidates with Its Corresponding Compound Types Listed by Investigator
Table 9: List of Biological Compounds
Table 10: List of Chemical Compounds
Table 11: List of Natural Compounds
Table 12: Developmental Stage and Sub Indication by Compounds Type in Leukemia
Table 13: Developmental Stage and Sub indication bt Compound Types in Lymphoma
Table 14: List of Targeted Therapies in Leukemia
Table 15: List of Targeted Therapies in Lymphoma
Table 16: Targeted Therapy Strategies Versus Compound Type in Leukemia
Table 17: Targeted Therapy Strategies Versus Compound Types in Lymphoma
Table 18: Targets Linking Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
Table 19: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
Table 20: Targets Linking Drugs to the Androgen Receptor Signaling Pathway
Table 21: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Androgen Receptor Signaling Pathway
Table 22: Targets Linking Drugs to the B Cell Receptor Signaling Pathway
Table 23: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the B Cell Receptor Signaling Pathway
Table 24: Targets Linking Drugs to the EGFR1 Signaling Pathway
Table 25: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the EGFR1 Signaling Pathway
Table 26: Targets Linking Drugs to the ID Signaling Pathway
Table 27: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the ID Signaling Pathway
Table 28: Targets Linking Drugs to the IL-1 Signaling Pathway
Table 29: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-1 Signaling Pathway
Table 30: Targets Linking Drugs to the IL-2 Signaling Pathway
Table 31: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-2 Signaling Pathway
Table 32: Targets Linking Drugs to the IL-3 Signaling Pathway
Table 33: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-3 Signaling Pathway
Table 34: Targets Linking Drugs to the IL-4 Signaling Pathway
Table 35: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-4 Signaling Pathway
Table 36: Targets Linking Drugs to the IL-5 Signaling Pathway
Table 37: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-5 Signaling Pathway
Table 38: Targets Linking Drugs to the IL-6 Signaling Pathway
Table 39: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-6 Signaling Pathway
Table 40: Targets Linking Drugs to the IL-7 Signaling Pathway
Table 41: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-7 Signaling Pathway
Table 42: Targets Linking Drugs to the Kit Receptor Signaling Pathway
Table 43: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Kit Receptor Signaling Pathway
Table 44: Targets Linking Drugs to theNotch Signaling Pathway
Table 45: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Notch Signaling Pathway
Table 46: Targets Linking Drugs to the T Cell Receptor Signaling Pathway
Table 47: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the T Cell Receptor Signaling Pathway
Table 48: Targets Linking Drugs to the TGF-beta Signaling Pathway
Table 49: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TGF-beta Receptor Signaling Pathway
Table 50: Targets Linking Drugs to the TNF-alpha Signaling Pathway
Table 51: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TNF-alpha Signaling Pathway
Table 52: Targets Linking Drugs to the Wnt Signaling Pathway
Table 53: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Wnt Signaling Pathway

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

惡性血液疾病相關全球藥物產品線動向及分析

Global Pipeline Review & Analysis of Hematological Malignancies